Press Releases VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-01 pm EST			5-day change	1st Jan Change
3.470 ^USD	+4.83%		-13.47%	+28.52%

Nov. 13	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	MT
Nov. 13	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 13	AQ
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023	Nov. 07	AQ
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million	Nov. 01	AQ
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202	Oct. 30	AQ
VYNE Therapeutics Announces Private Placement of $88 Million	Oct. 30	AQ
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo	Oct. 30	AQ
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	Sep. 06	AQ
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	Aug. 14	AQ
VYNE Therapeutics to Attend BIO International Convention	May. 18	AQ
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update	May. 11	AQ
University of Dundee : Spinout agrees potential $50 million deal	May. 03	AQ
VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	May. 01	AQ
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions	May. 01	AQ
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis	Apr. 19	AQ
VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201	Mar. 30	AQ
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference	Mar. 22	AQ
VYNE THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	Mar. 14	AQ
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update	Mar. 09	AQ
VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	Feb. 28	AQ
VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule	Feb. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Press Releases VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Press Releases

Filters